Drug Information

Drug General Information
Drug ID
D0I1DZ
Former ID
DIB008557
Drug Name
DE-110
Synonyms
Selective glucocorticoid receptor agonist (allergy), Santen
Indication Xerophthalmia [ICD10:E50.6-E50.7] Phase 2 [523248]
Company
Santen Pharmaceutical Co Ltd
Target and Pathway
Target(s) Glucocorticoid receptor Target Info Agonist [549039]
KEGG Pathway Neuroactive ligand-receptor interaction
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
FOXA2 and FOXA3 transcription factor networks
Glucocorticoid receptor regulatory network
Regulation of Androgen receptor activity
AP-1 transcription factor network
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling
SIDS Susceptibility Pathways
Nuclear Receptors Meta-Pathway
Endoderm Differentiation
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Adipogenesis
Circadian Clock
Nuclear Receptors
References
Ref 523248ClinicalTrials.gov (NCT01239069) Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease. U.S. National Institutes of Health.
Ref 549039Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031667)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.